Common Diabetes Drugs May Help Protect Hearing in Type 2 Diabetes Patients

Diabetes has long been recognized as a disease of blood vessels, nerves, kidneys, and eyes, but researchers are increasingly turning their attention to a quieter casualty of chronic high blood sugar: the inner ear. A new retrospective observational study conducted at the Audiology Section of the University of Palermo and published in Pharmacology Research & Perspectives suggests that type 2 diabetes is associated with measurably worse hearing thresholds, and that specific antidiabetic medications, particularly glucagon-like peptide-1 receptor agonists (GLP-1RAs) and metformin, may be linked to better-preserved auditory function. The findings, while exploratory, add an intriguing new dimension to the ongoing reassessment of what modern diabetes drugs can do beyond lowering glucose.

The research team analyzed medical records from 240 adults with documented type 2 diabetes who had undergone comprehensive audiological evaluation, alongside 105 normoglycemic control individuals drawn from the same clinical archive. Strict exclusion criteria were applied to sharpen diagnostic specificity: patients with type 1 diabetes, occupational noise exposure, acoustic trauma, conductive middle ear pathology, previous otological surgery, or current use of ototoxic medications were systematically removed from the analysis. Severe renal impairment, hereditary hearing loss, and syndromic deafness were also grounds for exclusion, minimizing confounding from uremia-induced auditory dysfunction and genetic forms of impairment. All participants provided written informed consent in accordance with Declaration of Helsinki principles.

Hearing function was assessed using standardized pure-tone audiometry performed with a clinical audiometer in a soundproof room. Micro-otoscopy ruled out middle ear pathology and active infection, while tympanometry confirmed stable middle ear mechanics. The primary outcome was the pure-tone average at speech frequencies, known as PTA-mean, calculated as the arithmetic mean of air-conduction thresholds at 0.5, 1, 2, and 4 kilohertz, the frequencies most critical for speech intelligibility. Lower PTA-mean values indicate better-preserved hearing, while higher values reflect greater impairment. For participants with asymmetric loss, thresholds from each ear were averaged to provide a representative global estimate, reducing ear-specific variability.

When the researchers compared diabetic and non-diabetic participants using analysis of covariance, adjusting for age, biological sex, body mass index, and smoking status, the presence of type 2 diabetes emerged as a statistically significant predictor of worse hearing thresholds. On average, diabetic patients showed PTA-mean values approximately 8 decibels higher than controls, a difference the authors describe as clinically meaningful, since a 10 decibel rise in auditory threshold is perceptually equivalent to halving perceived loudness. Notably, none of the demographic covariates, including age, reached statistical significance in the adjusted model, a result the authors attribute to the fact that the entire cohort consisted of individuals already diagnosed with sensorineural hearing loss, which compressed the natural variation in auditory function across ages.

The most provocative portion of the study examined whether specific antidiabetic treatments were associated with different auditory outcomes within the diabetic subgroup. Using multivariable linear regression adjusted for age and BMI, the team found that several agents stood out. Semaglutide and dulaglutide, two widely prescribed GLP-1 receptor agonists, were associated with substantially lower PTA-mean values, with large regression coefficients reflecting more favorable hearing thresholds. Metformin, the first-line biguanide used by 55 percent of the cohort, was also linked to better thresholds, and pioglitazone, a thiazolidinedione, showed a similar individual-level association. The remaining drug classes, including sulfonylureas, DPP-4 inhibitors, SGLT2 inhibitors, and glinides, showed no statistically significant connections to hearing outcomes.

When medications were grouped into pharmacological classes, GLP-1RAs again showed the strongest association, with roughly a 9.95 decibel reduction in PTA-mean compared with the reference category, and biguanides were associated with a smaller but significant reduction of about 4.05 decibels. Glinides showed a quantitatively relevant trend that narrowly missed statistical significance, while thiazolidinediones did not reach significance at the class level, likely because only 11 patients in the cohort were taking them. The overall drug-class model explained just over 5 percent of the variance in hearing thresholds, a modest figure consistent with the multifactorial nature of hearing loss, but the medication-related associations persisted even after adjustment for age and BMI, neither of which remained a significant predictor once drug class entered the model.

Why might GLP-1 receptor agonists and metformin be linked to healthier cochleae? The authors point to a convergence of plausible biological mechanisms. Diabetes-related hearing loss is thought to arise from cochlear microangiopathy that compromises blood flow to the stria vascularis, the metabolically demanding tissue that maintains the ionic gradients needed for sound transduction. Chronic hyperglycemia also floods the cochlea with reactive oxygen species, damaging the vulnerable outer hair cells, while advanced glycation end products, mitochondrial dysfunction, low-grade inflammation, and disruption of potassium and calcium homeostasis further erode cochlear and neural function. GLP-1RAs, in this framework, are appealing candidates for auditory protection because they enhance mitochondrial function, suppress inflammasome activation and pro-inflammatory cytokine production, reduce oxidative stress, and improve endothelial function, all of which may preserve the delicate microvascular perfusion the cochlea depends upon.

Metformin’s potential benefit rests on a different but complementary foundation. The drug is a pleiotropic agent that activates AMP-activated protein kinase, a cellular metabolic sensor governing mitochondrial biogenesis, oxidative stress defenses, and inflammatory responses. Through AMPK signaling, metformin may counteract the oxidative damage and microvascular dysfunction that characterize diabetic cochlear pathology, and its systemic metabolic and cardiovascular benefits could secondarily nourish ischemia-sensitive auditory tissue. Intriguingly, the authors note that metformin’s association with better hearing persisted after statistical adjustment, hinting that its potential auditory effects may not be mediated by glycemic control alone. The same logic applies across the medication spectrum: because every drug class studied effectively lowers blood glucose, the differential associations observed suggest that auditory preservation, if real, may stem from antioxidant, anti-inflammatory, and microvascular mechanisms rather than glucose lowering per se. Sulfonylureas, which stimulate insulin secretion without meaningful anti-inflammatory or antioxidant effects, fit neatly into this interpretation by showing no auditory association.

The authors are careful to frame these results as hypothesis-generating rather than practice-changing. The retrospective, non-interventional design precludes causal conclusions, and residual confounding from unmeasured variables, including diabetes duration, HbA1c levels, hypertension, renal function, cumulative drug exposure, treatment duration, and adherence, cannot be excluded. Because longitudinal audiometric follow-up was unavailable, hearing preservation was defined operationally as lower thresholds at a single assessment rather than demonstrated slowing of decline. Some treatment subgroups were small, making the large coefficients for individual agents particularly sensitive to sparse-data effects, outliers, and unmeasured clinical differences. The study also relied on pure-tone audiometry, which does not capture retrocochlear or central auditory processing, and included only hearing-impaired patients, which may explain why age failed to predict thresholds. The authors explicitly caution that the evidence is insufficient to support any change in antidiabetic prescribing based on hearing outcomes.

Even with these caveats, the implications are substantial. Diabetes already affects an estimated 589 million adults worldwide, and hearing loss, a historically underappreciated complication that erodes communication, social integration, and psychological well-being, may deserve a firmer place in routine diabetes care. The study’s authors suggest that audiological monitoring could become a useful adjunctive screening component of comprehensive diabetes management, particularly for older patients with long-standing disease or additional microvascular risk factors. If prospective studies confirm that GLP-1RAs and metformin are genuinely associated with slower auditory decline, hearing outcomes could eventually join cardiovascular and renal endpoints as extra-glycemic measures of treatment success, a notable prospect given the enormous clinical attention these drug classes already command. The mechanistic pathways outlined, from oxidative stress and microvascular inflammation to endothelial dysfunction, now await testing in experimental and translational studies that examine cochlear tissue directly, potentially yielding insights relevant to both diabetes-related and age-related hearing loss.

Subject of Research: Associations between antidiabetic pharmacotherapy and hearing thresholds in adults with type 2 diabetes and sensorineural hearing loss

Article Title: Associations Between Antidiabetic Pharmacotherapy and Hearing Thresholds in Adult Hearing‐Impaired Patients With Type 2 Diabetes

Article References: Martines, F., Salvago, P., Vaccaro, F., Vaccaro, D., Malta, G., Plescia, F., Cascioferro, S., Lavanco, G., & Plescia, F. (2026). Associations Between Antidiabetic Pharmacotherapy and Hearing Thresholds in Adult Hearing‐Impaired Patients With Type 2 Diabetes. Pharmacology Research & Perspectives, 14(5), Article e70316. https://doi.org/10.1002/prp2.70316

Image Credits: AI Generated

DOI: 10.1002/prp2.70316

Keywords: type 2 diabetes, hearing loss, GLP-1 receptor agonists, metformin, pure-tone audiometry, sensorineural hearing impairment, cochlear microangiopathy, oxidative stress, semaglutide, pioglitazone, diabetes complications, audiology